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1. Introduction 
In the last decade the use of Tumor Necrosis Factor- α inhibitors  including infliximab, 
etanercept, adalimumab; and lately certolizumab and golimumab, has revolutionized the 
treatment of rheumatoid arthritis (RA). These agents have been effective in reducing 
inflammatory activity and limiting joint destruction in patients with RA however their 
application has raised a number a safety concerns. Increased risk of infections is of 
predominant importance given these factors’ major role in altering host defense mechanisms.  
2. Infections in rheumatoid arthritis patients 
2.1 Background infection risk in patients with RA 
As infection adverse effects are common in patients with RA due to the underlying disease 
itself and/or concurrent medications used in its treatment such as immunosuppressants, it 
is of great importance to identify whether biological treatments increase this risk further 
(Furst 2010).  
Epidemiological studies prior the introduction of biological treatments have shown that 
patients with RA are at increased risk of certain types of infections including pulmonary 
infection, generalized sepsis, osteomyelitis, cellulitis, and septic arthritis with relative risks 
of infection - related mortality ranging from 5 to 15 (Mitchell, Spitz et al. 1986; Wolfe, 
Mitchell et al. 1994; Symmons, Jones et al. 1998). Nevertheless, the confounding influence of 
treatment with glycocorticoids and other disease –modifying antirheumatic drugs (DMRDs) 
is difficult to interpret. Disease it self leads to alterations in cellular immunity, including a 
decline in the number and function of T-suppressor and natural killer (NK) cells (Dobloug, 
Forre et al. 1982; Fox, Fong et al. 1984; Young, Adamson et al. 1984); changes that may 
predispose patients to infection. Other studies have suggested a genetic component to the 
risk of infection in RA. For example the incidence of urinary tract infection in patients with 
rheumatoid arthritis patients has been correlated with the number of risk alleles defined by 
single nucleotide polymorphisms in the genes for TNF-α, lymphotoxin–α and the Fcγ 
receptors 2A, 3A and 3B (Hughes, Criswell et al. 2004).  
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2.2 Bacterial infections 
2.2.1 Randomised controlled trials and extension studies of anti-TNF agents 
Infliximab 
The 1- year anti- TNF trial in Rheumatoid Arthritis with concomitant Therapy (ATTRACT 
study) reported similar incidences of infections among patients treated with infliximab (3 
or 10 mg/kg, given every 4 weeks or every 8 weeks) [1-5 patients (1–6%)] compared to 
patients receiving methotrexate (MTX) alone [5 patients (6%)]. (Maini, St Clair et al. 1999). 
The serious infections were described as bacterial infections, bronchitis, cellulitis, 
peritonitis, pneumonia, pyelonephritis and urinary tract infection, sepsis and tuberculosis, 
although the relative incidence of each of these infections was not reported. Notably, the 
frequency of any infection was significantly increased in patients receiving 10 mg/kg of 
infliximab, but not in those receiving 3 mg/kg. Similar incidence of serious infections was 
reported when ATTRACT was extended to 2 years (10-13%) (Maini, Breedveld et al. 2004). 
On the contrary, the incidence of serious infections in the 54 weak active controlled study 
of patients receiving infliximab for treatment of early onset RA (ASPIRE study) was 
significantly higher in the group receiving infliximab (3 or 6 mg/kg, given every 8 weeks 
in combination with MTX than in the group of patients receiving MTX monotherapy (St 
Clair, van der Heijde et at 2004. More specifically, serious infections included pneumonia, 
tuberculosis (TB), sepsis, bronchitis and septic bronchitis and occurred more commonly in 
patients receiving MTX -3 mg/kg infliximab [21 patients (5.6%)] or MTX -6 mg/kg 
infliximab [19 patients (5.0%)] than in those receiving MTX alone [6 patients (2.1%)] 
(P=0.02 and P=0.4, respectively). Among the serious infections, pneumonia occurred more 
frequently in the infliximab-treated patients than in those treated with MTX alone [15/749 
(2.0%) versus 0/291 (0.0%)]. According to the authors of the ASPIRE study most of these 
cases were community-acquired pneumonias that responded appropriately to antibiotic 
therapy. It has been suggested that the apparent differences in the incidence of severe 
infections between the ASPIRE and ATTRACT trials may reflect, at least partially, 
differences in study design. ASPIRE had substantially more patients enrolled (N=291-377 
per treatment arm, compared with 81-88 in ATTRACT) and in addition ASPIRE excluded 
patients that had prior treatment with MTX or anti-TNF while all patients in ATTRACT 
were receiving MTX at the time of the enrollment (Furst 2010). 
Etanercept 
With regards to etanercept, a 1 year study comparing MTX with 10 mg or 25 mg etanercept 
twice weekly reported similar number of patients with one or more infections in all 
treatment groups (Bathon, Martin et al. 2000). Interestingly, when the number of events that 
occurred per patient-year was analyzed, the rate of all types of infection was significantly 
higher among patients who received MTX than among those who received either dose of 
etanercept (1.9 vs. 1.5 events per patient-year, P=0.006). The frequency of upper respiratory 
tract infections was similar in the MTX group and the group assigned to receive 25 mg of 
etanercept, while the rate of infections at other sites in the respiratory tract was higher in the 
MTX group (1.3 vs. 1.0 events per patient-year, P=0.006). Infections requiring hospitalization 
or the intravenous administration of antibiotics occurred in less than 3% of patients in each 
group. There were no opportunistic infections, and no deaths from infections. When this 
study was extended to 2 years, similar incidences of serious infections in each treatment arm 
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were reported and did not increase in frequency during the second year of the study 
(Genovese, Bathon et al. 2002). Over the 2-year study period, 21 patients had infections that 
required hospitalization or use of intravenous antibiotics, including 9 patients in the MTX 
group, 5 patients in the 10 mg etanercept group, and 7 patients in the 25 mg group. The 
types of serious infection observed in the second year were similar to those reported in the 
first year and included cellulitis (1 patient each in all 3 treatment groups), bronchitis (1 
patient in the 10 mg group), pneumonia (1 patient in the 10 mg group), and cystitis (2 
patients in the 25 mg group); no cases of TB and no opportunistic infections were seen. 
Similarly, in a double-blind, randomized, clinical efficacy, safety, and radiographic study 
(TEMPO) involving 686 patients with active rheumatoid arthritis randomly allocated to 
treatment with etanercept 25 mg (administered subcutaneously twice a week), oral MTX (up 
to 20 mg every week), or the combination, similar incidences of infections and serious 
infections have been recorded in all treatment arms with no reports of TB or opportunistic 
infections (Klareskog, van der Heijde et al. 2004). Those results were sustained into the 2 
year follow up of the TEMPO trial showing similar rates of serious infections among all 
treatment groups (van der Heijde, Klareskog et al. 2006). Again, no cases of TB were 
reported but there was one case of bronchopulmonary aspergillosis in the combination 
therapy group. A similarly favorable safety profile for etanercept was reported from the 
ADORE study, which evaluated the efficacy and safety of combination etanercept and MTX 
versus etanercept alone in patients with RA with an inadequate response to MTX. The study 
showed comparable incidence of infections in the two arms and notably no cases of 
opportunistic infections or TB were reported in the combination group (van Riel, Taggart et 
al. 2006).  
Adalimumab 
The safety profile of adalimumab was initially evaluated in 3 double blind placebo 
controlled short term (24-26 weeks) trials reporting low incidence of serious infections (Furst, 
Schiff et al. 2003; van de Putte, Atkins et al. 2004; Weinblatt, Keystone et al. 2006). In a 
subsequent 52 weeks - long study comparing treatment with adalimumab (40mg every other 
week or 20 mg every week) plus concomitant MTX in patients with active RA who had an 
inadequate response to MTX, the proportion of patients with serious infections was higher 
in the group receiving adalimumab (3.8%) than in those receiving MTX (0.5%) (P≤0.02), and 
was highest in the patients receiving 40 mg adalimumab every other week (Keystone, 
Kavanaugh et al. 2004). Adjusting for exposure time, serious infections occurred at a rate of 
0.06 patients / patient-year with adalimumab 40 mg every other week, 0.03 patients per 
patient-year with adalimumab 20 mg weekly, and 0.01 patients per patient-year with MTX 
alone. One patient treated with adalimumab 40 mg every other week was diagnosed as 
having primary TB of the cervical lymph nodes, and nodes, was withdrawn from the study 
and successfully treated. At baseline, this patient had a negative tuberculin purified protein 
derivative (PPD) test result and a normal chest radiograph. One patient treated with 
adalimumab 40 mg every other week plus MTX was diagnosed with histoplasmosis 
infection after 78 days of treatment, and was subsequently withdrawn from the study and 
successfully treated with antifungal therapy. This patient lived in an area which was 
endemic for histoplasmosis infection. One patient treated with adalimumab 40 mg every 
other week was diagnosed as having herpes zoster and developed encephalitis, which 
resolved but resulted in mild lower extremity weakness. In the 2- year multicenter, double  
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blind, active Comparator-controlled study designed to compare the efficacy and safety of 
adalimumab plus MTX versus MTX monotherapy or adalimumab monotherapy in patients 
with early, aggressive RA who had not previously received MTX treatment (PREMIER 
study), the overall rate of infectious adverse events (AEs) did not differ significantly among 
the 3 treatment groups (123, 110, and 119 events per 100 patient-years in the combination 
therapy, adalimumab monotherapy, and MTX monotherapy groups, respectively) 
(Breedveld, Weisman et al. 2006). The rate of serious infections in the adalimumab 
monotherapy group was significantly lower than that in the combination treatment group, 
but not significantly different compared with the MTX monotherapy group. Notably, 
serious infections were more common in the combination therapy arm with 9 serious 
infections reported, including 3 pulmonary infections (1 case of pleural TB) and 1 case each 
of sinus infection, wound infection, septic arthritis, infected hygroma, cellulitis, and urinary 
tract infection. In the adalimumab monotherapy arm, serious infections included 1 case each 
of pneumonia, cellulitis, and septic arthritis. In the MTX monotherapy arm, the 7 serious 
infections consisted of 2 cases of pneumonia and 1 each of septic arthritis, sinusitis, abscess, 
bacteremia, and parotitis. The long term safety of adalimumab was investigated in the 4- 
year open-label extension of the ARMADA trial (Weinblatt, Keystone et al. 2006). The rate of 
serious infections was slightly lower throughout the entire study than in the blinded period 
alone with the most common serious infections reported being pneumonia, urinary tract 
infections and septic arthritis. A PPD skin test was performed at the screening visit for all 
patients. Standard chest radiographs were also taken at the screening visit and at week 24. 
Notably, at baseline, 11/271 (4.1%) randomized patients had positive PPD results at 
screening, including 9/209 (4.3%) adalimumab treated patients and 2/62 (3.2%) placebo 
treated patients. These patients were treated with TB prophylaxis in accordance with routine 
medical practice. No cases of TB or other opportunistic infections were reported. The safety 
profile of adalimumab was analyzed further in a cumulative analysis of data from 10050 
patients who participated in randomized controlled trials, open label extensions, and two 
phase IIIb open label trials, representing 12506 patient-years (PYs) of adalimumab exposure 
(Schiff, Burmester et al 2006). The rate of serious infections in the clinical trial safety 
database as of April 2005 was 5.1/100 PYs. This rate is nearly identical to that observed in 
August 2002 (4.9/100 PYs) and was similar to rates reported for the general RA population. 
Four cases of histoplasmosis were reported, all in endemic areas (0.03/100 PYs). No cases of 
coccidioidomycosis have been reported in RA clinical trials.  
2.2.2 Registry data, observational data and chart reviews 
The safety profile of anti-TNF agents in the everyday clinical practice was elucidated further 
by registry data analysis, observational studies and chart reviews. Data derived from these 
studies could be highly informative; however the lack of a standard comparator, strict 
inclusion and exclusion criteria and the inherent differences in patient characteristics with 
respect to ethnic, geographical and socio-economical characteristics often reduce their 
credibility and, produce desperate results and do not allow direct comparisons among 
different studies. Nevertheless, these studies become important when they investigate 
specific or relatively rare types of infections and raise specific concerns with regards to 
infections in certain population groups (Furst 2010).  
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In the German registry study, data of 512 patients receiving etanercept, 346 patients 
receiving infliximab, 70 patients receiving anakinra, and 601 control patients treated with 
disease-modifying antirheumatic drugs were analyzed. After adjusting for confounding 
factors, the relative risks of serious AEs were 2.2 [95% CI (confidence interval) 0.9–5.4] for 
patients receiving etanercept and 2.1 (95% CI 0.8–5.5) for patients receiving infliximab, 
compared to those treated with DMARDs. Respiratory tract infections were the most 
frequent followed by skin and subcutaneous tissue infections, influenza like illness, herpes 
virus infections, and urinary tract infections. Lower respiratory tract infections were the 
most common serious infections (Listing, Strangfeld et al. 2005). Updated results from the 
British Register for Biologic Therapies (BSRBR) (Galloway, Hyrich et al. 2011) also showed 
in contrary to previous reports (Dixon, Watson et al. 2006) that anti-TNF therapy is 
associated with a small but significant overall risk of serious infections. The adjusted hazard 
ratio (adjHR) for serious infections in the anti-TNF cohort was 1.2 (95% CI 1.1, 1.5). The risk 
did not differ significantly between the three agents adalimumab, etanercept and infliximab 
and it was highest during the first 6 months of therapy [adjHR (Hazard Ratio) 1.8, 95% CI 
1.3-2.6]. This was in accordance with the work of Askling and Dixon who reviewed all 
available studies on infection risk associated with anti-TNF therapy in RA and found that 
the risk was highest in the first few months but declined later during the course of treatment 
(Askling and Dixon 2008). It has been proposed that this variation in risk may reflect 
biological functions (anti-TNF therapy causing early infections in susceptible individuals), 
or bias (clinicians having a lower threshold for treating infections early in therapy). In 
addition the depletion of susceptible individuals (a healthy user effect) by withdrawing 
patients who develop an infection from the anti-TNF cohort may reduce the apparent risk of 
the drug through subsequent patient selection bias. Furthermore, as patients become 
established on anti-TNF therapy, their RA becomes better controlled and other confounding 
factors such as mobility may improve or their dose of steroids may be reduced thus 
contributing to the complexity of interpretation (Askling and Dixon 2008; Galloway, Hyrich 
et al. 2011).  
Registries and chart reviews can be particularly useful in identified specific infectious risks 
for susceptible patients. For example, data from the French registry estimated the relative 
risk of legionellosis when receiving treatment with a TNF-α antagonist to be between 16.5 
and 21.0, compared with the relative risk in France overall (Tubach, Ravaud et al. 2006).  
2.2.3 Case reports 
Numerous case reports have raised awareness to rare bacterial infections in RA patients 
treated with anti-TNF. These included reports on reactivation of brucellosis (Jimenez, 
Colmenero et al. 2005), Capnocytophaga cynodegmi-related cellulitis (Gerster and Dudler 
2004), Roseomonas mucosa induced septic arthritis (Sipsas, Papaparaskevas et al. 2006), and 
Propionebacterim acnes-related endogenous endophthalmitis (Montero, Ruiz-Moreno et al. 
2006). 
2.2.4 Meta-analyses 
One solution to the lack of precision in the estimates of harm derived from individual 
randomized trials is to pool their results using meta-analysis. Results however from the two 
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existing meta-analyses studies on anti-TNF therapy and risk of infection are disparate. A 
meta-analysis of nine randomized, controlled studies including 3493 patients with RA who 
received anti-TNF antibody treatment (infliximab and adalimumab) and 1512 patients who 
received placebo reported a doubled risk of serious infection [odds ratio (OR) 2.0, 95% CI 
1.3–3.1] and a tendency towards a dose–response association (Bongartz, Sutton et al. 2006). 
On the contrary, a second meta-analysis of five published, placebo-controlled trials 
involving a total of 2945 randomized patients, who received at least one dose of abatacept 
(0.5, 2 or 10 mg/kg) (n=1960) or placebo (n=985) for a duration of treatment ranging 
between 24 and 48 weeks did not reveal a statistically significant increased risk of serious 
infection for abatarcept (Salliot, Dougados et al. 2009). The 49 serious infections reported in 
the abatacept cohort were mainly broncho-pulmonary, streptococcal and pyogenic 
septicaemia, staphylococcal arthritis, abscesses, gastrointestinal infections (6 of whom 3 
diverticulitis), dermatological infections (six of whom one was a cellulitis) and 
pyelonephritis. One case of unconfirmed TB and one case of pulmonary aspergillosis were 
reported. The last patient (who had a history with TB and pulmonary fibrosis) died with 
aspergillosis and Pseudomonas aeruginosa septicaemia.  
2.3 Tuberculosis and opportunistic infections 
As shown earlier, the incidence of TB in pre-registration clinical trials has been low. It was 
only after licensing of these medications that post-marketing surveillance registers showed 
results suggestive a strong association between ant-TNF treatment and TB. Keane et al 
analysed data from the US Food and Drug Administration’s ( FDA) Adverse Event 
Reporting System (AERS) for reports of TB with infliximab from its licensure in 1998 
through May 29, 2001 (Keane, Gershon et al. 2001). There were 70 reported cases of TB after 
treatment with infliximab for a median of 12 weeks. In 48 patients, TB developed after three 
or fewer infusions and 40 of the patients had extrapulmonary disease (17 had disseminated 
disease, 11 lymph-node disease, 4 peritoneal disease, 2 pleural disease, and 1 each 
meningeal, enteric, paravertebral, bone, genital, and bladder disease). An estimated rate of 
24.4 cases of tuberculosis per 100 000 in the USA compared with a background rate in 
American patients with RA who had not received the drug of 6.2 cases per 100000 was 
calculated. The rather atypical presentation of the disease (e.g. extrapulmonary 
dissemination), the temporal relation between development of active tuberculosis and the 
start of therapy, the age of the patients (median, 57 years), the small number of cases with 
reported recent exposure to TB, and the low incidence of TB in the countries from which the 
reports were received suggested reactivation of the disease (Keane, Gershon et al. 2001).  
As of March, 2002, 121000 patients had been treated with etanercept worldwide with about 
94% of the use in the USA. In a search of the FDS’s AERS database reported up to March 
2002, Mohan and co-workers detected 25 cases of tuberculosis that occurred during or after 
etanercept therapy (Mohan, Cote et al. 2004). Patients with etanercept-associated TB were 
fewer but clinically similar to those with infliximab-associated TB (Keane, Gershon et al. 
2001). The numbers of patients who had been exposed to etanercept and infliximab were 
roughly similar, yet the TB rate for US patients using etanercept was lower than that for 
patients using infliximab (∼10 vs. ∼41 cases/100000 patient-years of exposure). It has been 
proposed that this difference might be due to the divergent ways in which the 2 agents 
neutralize TNF-α, the use of MTX concurrently with infliximab (as indicated for RA in the 
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infliximab package insert), differences in proportions of international patients treated with 
the 2 agents, or other factors (Gardam, Keystone et al. 2003; Mohan, Cote et al. 2004). 
Overall, in a large systematic review of infectious complications of TNF antagonists 
extracted from 35275 distinct reports from the AERS database between for January 1998–
September 2002, granulomatous infections were reported at rates of ∼239 per 100000 
patients who received infliximab and ∼74 per 100,000 patients who received etanercept (P 
<0.001) (Wallis, Broder et al. 2004). TB was the most frequently reported disease, occurring 
in ∼144 and ∼35 per 100,000 infliximab-treated and etanercept-treated patients, respectively 
P<0.001. Candidiasis, coccidioidomycosis, histoplasmosis, listeriosis, nocardiosis, and 
infections due to nontuberculous mycobacteria were reported with significantly greater 
frequency among infliximab-treated patients. 72% of these infection occurred 90 days after 
starting infliximab treatment, and 28% occurred after starting etanercept treatment P<0.001. 
These data indicated a relative risk of granulomatous infection that was >3 among patients 
who received infliximab compared to those who received etanercept. The clustering of 
reports shortly after initiation of treatment with infliximab was consistent with reactivation 
of latent infection.  
Geographical associations between anti-TNF therapy and specific granulomatous diseases 
have been suggested. For example, disseminated histoplasmosis has been reported more 
frequently in endemic regions in the US (Lee, Slifman et al. 2002). In a review of the FDA 
passive surveillance database, nine cases of invasive disseminated histoplasmosis associated 
with infliximab and 1 associated with etanercept were reported. In patients treated with 
infliximab, manifestations of histoplasmosis occurred within 1 week to 6 months after the first 
dose and typically included fever, malaise, cough, dyspnea, and interstitial pneumonitis. All 
patients had received concomitant immunosuppressive medications in addition to infliximab 
or etanercept, and all resided in histoplasmosis endemic regions of central US (Lee, Slifman et 
al. 2002). Similarly, anti-TNF therapy was shown to be associated with increased reports of 
leishmaniasis in endemic areas in Europe (Xynos, Tektonidou et al. 2009).  
A major factor that has influenced data relating to the risk of TB associated with biological 
treatments has been the introduction of vigorous screening of patients participating in 
clinical trials; hence rates for newer biological agents such as abatarcept may be biased. 
Screening for TB exposure with PPD skin testing or newer interferon-based serum tests 
(although their optimal use in this setting is not yet clear) should be performed before 
beginning therapy with anti-TNF agents (Winthrop and Chiller 2009). Anergy is known to 
occur in patients with RA or Crohn’s disease, and the possibility of false-negative skin tests 
should be taken into consideration. Nevertheless from a therapeutic point of view, since the 
implementation of strict guidelines (e.g. BTS recommendations, 2005) with regards to 
screening patients for exposure risks and treating latent TB prior to initiation of any 
biological treatment, the risk of tuberculosis has decreased. This is depicted in the data from 
the Spanish Registry showing that these strategies have resulted in dropping the rates of 
active TB in RA patients by 83% reaching those observed for RA patients not treated with 
TNF antagonists (Carmona, Gomez-Reino et al. 2005). 
2.3.1 TNF-α pathophysiology and infections 
TNF is essential for granuloma formation and maintenance which are key components of 
host defences against intracellular pathogens (Furst, Wallis et al. 2006). TNF can support 
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host immunity through the secretion of chemokines, up-regulation of adhesion molecules 
and the induction of macrophage apoptosis. While TNF blockers may therefore interfere 
with these important immune functions, other less predictable immune effects have been 
seen with these agents. In particular, TNF-blockers have been shown to diminish interferon 
(IFN)-γ effects and stimulate apoptosis of key immune cells, including monocytes, CD4+ T 
helper cells and Mtb-reactive CD8+ T cells. Anti-TNF therapy is also associated with 
increased regulatory T cell (Treg) function, which has been linked with susceptibility to TB 
(Harris and Keane 2010). TNF-α neutralization in mice has resulted in fatal reactivation of 
persistent tuberculosis characterized by a moderately increased tissue bacillary burden and 
severe pulmonic histopathological deterioration that was associated with changes indicative 
of squamous metaplasia and fluid accumulation in the alveolar space (Mohan, Scanga et al. 
2001). 
2.4 Postoperative infections 
Although several studies have attempted to address the risk of postoperative infection, 
limited statistical precision has been a major concern. The largest study reported a 50% (but 
not statistically significant) increased risk of surgical site infections for those patients who 
continued therapy peri-operatively (den Broeder, Creemers et al. 2007). Nevertheless, 
considering the morbidity of orthopedic surgical site infections (especially prosthesis 
infections) as compared to a transient surge in disease activity, withholding anti-TNF agents 
peri-operatively appears to be the most reasonable and prudent approach at present 
(Bongartz 2007).  
2.5 Viral infections 
Reactivation of Hepatitis B (HBV) infection is a well described complication of 
immunosuppression in the setting of organ transplantation or cancer chemotherapy, 
occurring in up to 50% of patients where concomitant anti-viral treatment is not applied 
(Shale, Seow et al. 2010). The use of anti-TNF medications has been reported in isolated case 
reports, case series and chart reviews with a variety of outcomes ranging from apparent 
viral clearance to fatal hepatitis. In a comprehensive review of these cases by Zingarelli at al 
involving 27 HBV-infected patients treated with anti-TNF agents, HBV reactivation was 
documented in 14% of patients treated with lamivudine compared with 73% of patients not 
receiving HBV prophylaxis (Zingarelli, Frassi et al. 2009) thus suggesting that the use of 
prophylactic lamivudine could help reducing the risk of HBV reactivation. More recently, 
interesting data with regards to the relative safety of anti-TNF agents in HBV carriers were 
presented by Charpin et al (Charpin, Guis et al. 2009). Their cohort included 21 patients with 
serologically cured HBV infection, that is HBsAg –ve plus anti-HBc +ve patients and results 
were suggestive that anti-TNF therapy appeared to be safe during the a limited follow up 
period of three years. Nevertheless, about 30% of patients involved in this study had 
significant lower antibody titers over the follow up period which may be relevant during 
long-term follow up (Jansen 2010). Similar findings we reported by others over a shorter 
follow up period of 2 years (Vassilopoulos, Apostolopoulou et al. 2010) yet the decrease in 
antibody titers observed in the later study was comparable to that observed in a control 
group of patients treated with MTX alone, indicating no apparent specific effect of anti-TNF 
on HBV protective immunity.  
www.intechopen.com
 
Infectious Complications of Anti-Tumour Necrosis Factor-α Therapy in Rheumatoid Arthritis 
 
101 
Anti-TNF therapy for RA in the setting of Hepatitis C (HCV) infection could be of particular 
interest in light of the existing evidence suggesting a role for inflammatory cytokines 
including TNF-α in the mediating hepatocyte destruction in chronic CMV (Parke and 
Reveille 2004). It may therefore carefully assumed that anti-TNF agents may be safer in 
patients infected with HCV rather than HBV (Shale, Seow et al. 2010) and furthermore this 
notion has been tested in a phase 2 randomised, double-blind, placebo-controlled study 
where etanercept given for 24 weeks as adjuvant therapy to interferon and ribavirin was 
shown to significantly improve virological response among patients with chronic HCV and 
was associated with decreased incidence of most adverse effects associated with interferon 
and ribavirin (Zein 2005). Although overall experience to date with anti-TNF agents in the 
chronic HCV setting suggests an acceptable short-term safety profile (Marotte, Fontanges et 
al. 2007), long-term issues remain to be clarified.  
The safety of anti-TNF therapy in HIV is a controversial subject. TNF inhibition in the 
setting of HIV induced immunosuppression does not appear appealing in view of the 
potential role for TNF-α in the host defence against infections. Notably, in an early report, 
the use of etanercept in HIV positive patient with psoriasis and CD4 count of <200/mm3 
was associated with polymicrobial infections prompting termination of the treatment 
(Aboulafia, Bundow et al. 2000). Subsequent reports though have shown a favourable safety 
profile (Kaur, Chan et al. 2007; Cepeda, Williams et al. 2008), yet clinical decisions should be 
taken cautiously; careful consideration of the risks and benefits for the individual patient 
would be needed and close clinical and virological monitoring should always be warranted.  
The safety of TNF inhibitors in patients with herpes virus (HSV) infections has also been 
considered. In particular the risk of herpes zoster infection in patients with RA is twice as 
much even in the absence of therapy (Wolfe, Michaud et al. 2006; Smitten, Choi et al. 2007) 
and severe herpes zoster infections have been reported in randomised controlled trials and 
their open-label follow up studies in patients with RA receiving the TNF inhibitors 
infliximab or adalimumab (Lipsky, van der Heijde et al. 2000; Furst, Schiff et al. 2003; 
Keystone, Kavanaugh et al. 2004; Maini, Breedveld et al. 2004). A study by Strangfeld et al 
(Strangfeld, Listing et al. 2009) addressed the question whether this association actually 
represents a true association between TNF inhibitors reactivation of latent viral infections or 
simply reflects the increased risk of herpes zoster infection in RA patients (Bongartz and 
Orenstein 2009). In this prospective cohort the investigators identified 86 episodes of herpes 
zoster among 5040 patients from the German biologics register RABBIT, receiving anti-TNF 
agents or conventional DMARDs. Adjusted for age, RA severity and glucocorticoid use, a 
significant increased risk was observed for treatment with the monoclonal antibodies (HR, 
1.82 [95% CI, 0.73-2.55]), although this risk was lower than the threshold (of 2.5) for clinical 
significance. No significant associations were found for etanercept use (HR 1.36, 95% CI 
0.73-2.55) or for anti-TNF treatment (HR 1.63, 95% CI 0.97-2.74) as a class. Equally 
important, the incidence rate of multidermatomal and ophthalmic zoster was higher in 
patients taking TNF inhibitors implying severe disease often requiring hospitalisation 
(Bongartz and Orenstein 2009). Nevertheless, anti-TNF therapy can generally be restarted 
following temporary interruption and conventional anti-viral therapy until the skin lesions 
are completely healed (Wendling, Streit et al. 2008). Isolated varicella infections have also 
been reported in RA patients receiving anti-TNF therapy (Vonkeman, ten Napel et al. 2004; 
Choi, Kim et al. 2006; Lee, Kim et al. 2007). Notably the rash in one of these cases was 
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atypical (Choi, Kim et al. 2006) stressing the need for high index of suspicion upon 
diagnosing primary varicella infection in susceptible patients with atypical skin lesions.  
Finally, although a prospective study involving 15 patients with refractory forms of RA 
under treatment with infliximab (3 mg/kg) did not show evidence of lymphotropic 
herpesviruses reactivation (CMV, HHV-6, HHV-7, HHV-8, EBV) in RA patients (Torre-
Cisneros, Del Castillo et al. 2005), two isolated case reports have associated infliximab with 
HHV8 related Kaposi’s sarcoma (Cohen, Horster et al. 2003) and cytomegalovirus (CMV) 
retinitis (Haerter, Manfras et al. 2004). 
2.6 Response to vaccination 
As patients with RA receiving conventional DMARDs and biologics are at increased risk of 
vaccine preventable diseases such as respiratory tract infections caused by H. Influenza and 
S. Pneumoniae, safety and efficacy evaluation of vaccines in this setting is of paramount 
importance. The use of TNF inhibitors in particular has raised specific concerns with regards 
to their potential influence on antibody responses to vaccination. The potential influence of 
anti-TNF inhibition on the efficacy of influenza vaccination was evaluated in a prospective 
cohort study involving 149 patients with RA including 50 patients treated with TNF 
blockers (etanercept or infliximab) in combination with MTX, 62 patients receiving TNF 
blockers alone or with other DMARDs and 37 patients treated with MTX alone plus 18 
healthy controls (Kapetanovic, Saxne et al. 2007). Vaccination with trivalent vaccine resulted 
in better serological response in RA patients treated with MTX without TNF inhibitors 
compared with those receiving TNF inhibitors alone or in combination with MTX and/or 
other DMRDS. Nevertheless, the immune response according to the authors was sufficiently 
large to warrant influenza vaccination to all RA patients regardless of treatment. Similar 
results were reported by others (Fomin, Caspi et al. 2006). Equally reassuring were results 
from studies investigating the efficacy of pmeumococcal vaccine in RA patients receiving 
anti-TNF therapy. In one study, immune response to 23-valent pneumococcal vaccine was 
better in patients treated with TNF inhibitors without MTX compared to those treated with 
TNF inhibitors in combination with MTX or MTX alone. Response rates were 50, 31 and 13% 
for the TNF inhibition without MTX, TNF inhibition with MTX and MTX groups 
respectively (Kapetanovic, Saxne et al. 2006). In a different prospective cohort of RA patients 
receiving either adalimumab or placebo, investigators reported that following 
pneumococcal vaccination, the percentage of patients achieving a vaccine response were 
similar in the adalimumab and placebo groups [37.4% and 40.4%, respectively; 95% CI -
16.2%, 10.3%]. Equally similar was the percentage of patients with protective antibody titres 
in both treatment groups (adalimumab: 85.9%, placebo: 81.7%) (Kaine, Kivitz et al. 2007 ). 
Thus, anti-TNF therapy should not deter physicians from offering patients with RA 
vaccination against H. Influenza and S. Pneumoniae.  
3. Conclusions and future directions 
TNF-α blockade strategies have revolutionized the treatment RA, raising though safety 
concerns with regards to increased risk for infections. Although pre-registration clinical 
trials for TNF inhibitors showed no clear increased risk for infections, long term clinical 
trials and post registrations studies have shown a small but consistent increase in infection 
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risk in patients treated with anti-TNF therapy compared to those treated with conventional 
DMARDs. Common infections involve sites as the respiratory tract, skin and soft tissue and 
the urinary tract. The risk of M. tuberculosis infection also appear to be increased with the 
use of these agents and is highest during the first 6 months of therapy, most probably 
reflecting reactivation of latent TB. Screening patients for exposure risks and latent TB prior 
to the initiation of anti-TNF therapy and administration of standard chemo-prophylaxis has 
decreased the incidence of new TB cases. Other opportunistic infections such as 
histoplasmosis, coccidioidomycosis and leishmaniasis may occur following geographical 
criteria, indicating increased incidence of these illnesses in endemic areas. In view of the 
increased infectious risk associated with these agents, we should reiterate the importance of 
efficient pre-treatment screening and close monitoring of patients throughout their 
treatment. Physicians should be aware of infectious diseases endemic to their geographic 
area and be vigilant for unusual presentation of symptoms and signs of infectious illnesses. 
They should stop biologic therapy when these occur, treat those infectious complications 
promptly and report such cases to regulatory or public health authorities where 
appropriate. As new biological agents are developed and reach the market place, large scale 
post marketing surveillance with registry studies and other observational studies will be 
needed to establish the long term safety profile of these novel therapies. 
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